Filter zurücksetzen
Stichworte
Behandlungsbedürftigkeit, Begutachtung ×
Zeige mehr Stichworte
Inhaltsverzeichnis
  1. 1. Klinische Studie
  2. 2. Routinedokumentation
  3. 3. Register-/Kohortenstudien
  4. 4. Qualitätssicherung
  5. 5. Datenstandard
  6. 6. Patientenfragebogen
  7. 7. Medizinische Fachrichtung
    1. 7.1. Anästhesie
    1. 7.2. Dermatologie
    1. 7.3. HNO
    1. 7.4. Geriatrie
    1. 7.5. Gynäkologie/Geburtshilfe
    1. 7.6. Innere Medizin
      1. Hämatologie
      1. Infektiologie
      1. Kardiologie/Angiologie
      1. Pneumologie
      1. Gastroenterologie
      1. Nephrologie
      1. Endokrinologie/Stoffwechsel
      1. Rheumatologie
    1. 7.7. Neurologie
    1. 7.8. Augenheilkunde
    1. 7.9. Palliativmedizin
    1. 7.10. Pathologie/Rechtsmedizin
    1. 7.11. Kinderheilkunde
    1. 7.12. Psychiatrie/Psychosomatik
    1. 7.13. Radiologie
    1. 7.14. Chirurgie
      1. Allgemein-/Viszeralchirurgie
      1. Neurochirurgie
      1. Plastische Chirurgie
      1. Herz-/Thoraxchirurgie
      1. Unfallchirurgie/Orthopädie
      1. Gefäßchirurgie
    1. 7.15. Urologie
    1. 7.16. Zahnmedizin/MKG
Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

78 Suchergebnisse.
Relevanz Bewertung Neue zuerst Alte zuerst

Eligibility HIV Infection NCT02323308

- 29.02.20 - 1 Formular, 2 Itemgruppen, 12 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Isolated Anti-HBc Serological Profile in HIV Infected Patients: Immunological, Virological Characteristics and Response to Hepatitis B Vaccination; ODM derived from: https://clinicaltrials.gov/show/NCT02323308

Safety and efficacy of topical Retapamulin Ointment vs. oral Linezolid in Secondarily-Infected Traumatic Lesions and Impetigo due to MRSA, NCT00852540 - Eligibility criteria

- 07.03.19 - 1 Formular, 4 Itemgruppen, 30 Datenelemente, 1 Sprache
Itemgruppen: Administrative data, Eligibility question, Inclusion criteria, Exclusion criteria
Study ID: 110978 Clinical Study ID: 110978 Study Title: A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus aureus Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00852540 https://clinicaltrials.gov/ct2/show/NCT00852540 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Retapamulin Ointment, Oral Linezolid Trade Name: N/A Study Indication: Skin Infections, Bacterial The study consists of 5 vists. The studys period extends over 19 days: Visit 1 (Day 1): Baseline (for both, topical and oral visit) Visit 2 (Day 3-4): On-Therapy (for both, topical and oral visit) Visit 3 (Day 7-9): End of Therapy for topical visit, On-Therapy for oral visit. Visit 4 (Day 12-14): Follow-up for topical visit, End of Therapy for oral visit. Visit 5 (Day 17-19): Final Follow-up for topical visit, Follow-up for oral visit. This document contains the eligibility criteria form. It has to be filled in for screening.

Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons 00079911 - Eligibility Question

- 01.02.19 - 1 Formular, 4 Itemgruppen, 23 Datenelemente, 1 Sprache
Itemgruppen: Administrative, Eligibility Question, Inclusion Criteria, Exclusion criteria
Study ID: 100181 Clinical Study ID: 100181 Study Title: A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00079911 Sponsor: GlaxoSmithKline Phase: Phase 4 Study Recruitment Status: Completed Generic Name: valacyclovir hydrochloride Trade Name: Valaciclovir Study Indication: Herpes Simplex Virus (HSV)

Eligibility HCMV Infection NCT01113359

- 27.12.18 - 1 Formular, 2 Itemgruppen, 9 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
The Link Between Human Cytomegalovirus (HCMV) and Hypertension; ODM derived from: https://clinicaltrials.gov/show/NCT01113359

Eligibility Bloodstream Infection in Cancer Patient DRKS00003368 NCT01544686 DRKS00003368 - Eligibility Bloodstream Infection in Cancer Patient NCT01544686 DRKS00003368

- 04.07.17 - 1 Formular, 2 Itemgruppen, 15 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Responsible Party: Maria J.G.T. Vehreschild, Principal Investigator, University of Cologne ClinicalTrials.gov Identifier: NCT01544686 History of Changes Other Study ID Numbers: DRKS00003368 Study First Received: February 22, 2012 Last Updated: December 8, 2015 Antimicrobial Catheter Securement Dressings for the Prevention of Cvc-related Bloodstream Infections in Cancer Patients (COAT) ODM derived from: https://clinicaltrials.gov/ct2/show/NCT01544686

Eligibility Hepatitis C, Chronic NCT01447420

- 20.09.21 - 1 Formular, 2 Itemgruppen, 15 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin); ODM derived from: https://clinicaltrials.gov/show/NCT01447420

Eligibility NCT00803309 Hepatitis C, Chronic - Eligibility Hepatitis C NCT00803309

- 20.09.21 - 1 Formular, 2 Itemgruppen, 35 Datenelemente, 2 Sprachen
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Chronic Hepatitis C: Optimization of Treatment for Patients infected With HCV-genotype 2 or 3: 12 vs. 24 Weeks of Treatment Extension for Patients Without Rapid Virological Response see http://clinicaltrials.gov/show/NCT00803309

Eligibility Hypertension NCT02188381

- 09.04.20 - 1 Formular, 2 Itemgruppen, 12 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
The Role of Gut Microbiota in Hypertension; ODM derived from: https://clinicaltrials.gov/show/NCT02188381

Eligibility Hepatitis C, Chronic NCT01750216

- 14.02.20 - 1 Formular, 2 Itemgruppen, 12 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1; ODM derived from: https://clinicaltrials.gov/show/NCT01750216

Eligibility Hepatitis C, Chronic NCT01606800

- 13.02.20 - 1 Formular, 2 Itemgruppen, 14 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059); ODM derived from: https://clinicaltrials.gov/show/NCT01606800

Eligibility Hepatitis C, Chronic NCT01585324

- 13.02.20 - 1 Formular, 2 Itemgruppen, 18 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a); ODM derived from: https://clinicaltrials.gov/show/NCT01585324

Eligibility Hepatitis C NCT01146626

- 03.02.20 - 1 Formular, 2 Itemgruppen, 15 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Does Vitamin D Improves Sustained Virologic Response (SVR) in Genotype 2,3 Chronic Hepatitis C Patients?; ODM derived from: https://clinicaltrials.gov/show/NCT01146626

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video